Lowenstein Jensen + Pefloxacin (2)* price on request
- Known as:
- Lowenstein Jensen + Pefloxacin (2)* price request
- Catalog number:
- MB-34136
- Product Quantity:
- 50 tubes
- Category:
- -
- Supplier:
- Kisbio
- Gene target:
- Lowenstein Jensen + Pefloxacin (2)* price request
Related genes to: Lowenstein Jensen + Pefloxacin (2)* price on request
- Gene:
- A1BG-AS1 NIH gene
- Name:
- A1BG antisense RNA 1
- Previous symbol:
- NCRNA00181, A1BGAS, A1BG-AS
- Synonyms:
- FLJ23569
- Chromosome:
- 19q13.43
- Locus Type:
- RNA, long non-coding
- Date approved:
- 2009-07-20
- Date modifiied:
- 2013-06-27
- Gene:
- A2ML1 NIH gene
- Name:
- alpha-2-macroglobulin like 1
- Previous symbol:
- CPAMD9
- Synonyms:
- FLJ25179, p170
- Chromosome:
- 12p13.31
- Locus Type:
- gene with protein product
- Date approved:
- 2005-07-20
- Date modifiied:
- 2018-04-17
- Gene:
- A2MP1 NIH gene
- Name:
- alpha-2-macroglobulin pseudogene 1
- Previous symbol:
- A2MP
- Synonyms:
- -
- Chromosome:
- 12p13.31
- Locus Type:
- pseudogene
- Date approved:
- 1991-09-12
- Date modifiied:
- 2016-08-22
- Gene:
- A3GALT2 NIH gene
- Name:
- alpha 1,3-galactosyltransferase 2
- Previous symbol:
- A3GALT2P
- Synonyms:
- IGBS3S, IGB3S
- Chromosome:
- 1p35.1
- Locus Type:
- gene with protein product
- Date approved:
- 2005-05-06
- Date modifiied:
- 2018-02-08
- Gene:
- AACS NIH gene
- Name:
- acetoacetyl-CoA synthetase
- Previous symbol:
- -
- Synonyms:
- FLJ12389, SUR-5, ACSF1
- Chromosome:
- 12q24.31
- Locus Type:
- gene with protein product
- Date approved:
- 2003-06-02
- Date modifiied:
- 2015-08-24
Related products to: Lowenstein Jensen + Pefloxacin (2)* price on request
110V-to-100V Voltage Transformer 5 A capacity. Net price (not negotiatable). Voltage transformer may be locally prepared, instead of purchasing from Atto.110V-to-100V Voltage Transformer 5 A capacity. Net price (not negotiatable). Voltage transformer may be locally prepared, instead of purchasing from Atto.2,4,5_Tri_chlorophenoxyacetic Acid *Price on request240V-to-100V Voltage Transformer 5 A capacity. Net price (not negotiatable). Voltage transformer may be locally prepared, instead of purchasing from Atto.240V-to-100V Voltage Transformer 5 A capacity. Net price (not negotiatable). Voltage transformer may be locally prepared, instead of purchasing from Atto.anti_CENP_A(fission yeast)antibody, rabbit antibody*price on requestanti_Cnd2(fission yeast)antibody, rabbit antibody*price on requestanti_Cut15(fission yeast)antibody, rabbit antibody*price on requestanti_Cut8(fission yeast)antibody, rabbit antibody*price on requestanti_Cut9(fission yeast)antibody, rabbit antibody*price on requestanti_Dis1(fission yeast)antibody, rabbit antibody*price on requestanti_Dis1(P_S551)(fission yeast)antibody, rabbit antibody*price on requestanti_Mis4(fission yeast)antibody, rabbit antibody*price on requestanti_Nda4(fission yeast)antibody, rabbit antibody*price on requestanti_NIPBL(human,hMis4)antibody, rabbit antibody*price on request Related articles to: Lowenstein Jensen + Pefloxacin (2)* price on request
- Chronic non-bacterial osteomyelitis (CNO) is an autoinflammatory bone disease primarily affecting children and adolescents. The condition is characterised by bone pain, hyperostosis, and bone deformities, impacting patients' quality of life. Although CNO is the second most common inflammatory rheumatic disease in childhood, no licensed treatments exist. Clinical trials have been challenged by the absence of validated classification criteria and inclusion and exclusion criteria, a shortage of well-validated tools to measure treatment response, and a small market for commercialisation. Clinical trials are urgently needed to generate evidence and allow licensing of medications. Since 2022, long-standing challenges, previously hindering trial design and delivery in CNO, have been addressed through the development of classification criteria, expert consensus on inclusion and exclusion criteria, and the development of outcome measures. Applying a platform trial design testing treatments against a common comparator promises to deliver several key benefits for patients with CNO, families, and health-care services. This Viewpoint summarises treatments currently used to treat CNO alongside promising future candidates, outlining challenges in trial design and how these have, partly, been overcome. - Source: PubMed
Hedrich Christian MRoberts EveInguscio GiuliaRamanan Athimalaipet V - - Source: PubMed
Publication date: 2027/06/30
Arya Nezhad ShefaRastgou ParvanehNanna Michael G - Residual neuromuscular blockade is a potential contributor to postoperative pulmonary complications, particularly in obese patients undergoing abdominal surgery. Continued reliance on qualitative neuromuscular monitoring and underutilization of sugammadex highlight a critical gap between evidence and practice. The low incidence of severe complications necessitates large studies to assess the impact of practice changes on clinical outcomes. The incidence and magnitude of postoperative hypoxemia may serve as a marker for other, more severe adverse outcomes. This before/after study evaluated the impact of a structured protocol incorporating quantitative train-of-four monitoring and weight-based sugammadex dosing on postoperative hypoxemia as documented by a continuous monitoring system. - Source: PubMed
Publication date: 2026/08/10
Fleming Neal WBarrameda Bryle Nicole GLi DavidFurukawa Kenneth T - : Large-volume benign prostatic hyperplasia (≥80 mL) requires complete anatomical removal of the adenoma. Robot-assisted or minimally invasive simple prostatectomy (RASP/MISP) and anatomic endoscopic enucleation of the prostate (AEEP) have both emerged as minimally invasive alternatives to open simple prostatectomy, but their comparative perioperative performance in very large glands remains incompletely defined. : To systematically review and quantitatively synthesize the perioperative outcomes and complications of RASP/MISP versus AEEP in the surgical management of large-volume BPH. : Following PRISMA 2020, PubMed, Embase, Scopus and the Cochrane Library were searched from inception to 7 June 2026 for randomized and non-randomized comparative studies of RASP/MISP versus AEEP in men with mean or median prostate volume ≥ 80 mL reporting at least one perioperative or functional outcome and at least one Clavien-Dindo grade ≥ III complication. Continuous outcomes were pooled as mean differences (MD) and dichotomous outcomes as risk ratios using random-effects models (REML with Knapp-Hartung adjustment); heterogeneity was assessed with I. Risk of bias was evaluated with the Newcastle-Ottawa Scale and ROBINS-I, and certainty of evidence with GRADE. Publication bias and leave-one-out sensitivity analyses were performed where the number of studies permitted. : Five comparative cohort studies published between 2017 and 2025 were included, comprising 271 patients treated with RASP/MISP and 998 treated with AEEP. AEEP was associated with a significantly shorter catheterization time (pooled MD 5.95 days; 95% CI 1.98-9.92; = 0.014) and a shorter hospital stay (pooled MD 2.73 days; 95% CI 1.07-4.39; = 0.010), both with high heterogeneity (I 99.0% and 96.1%, respectively). Perioperative hemoglobin drop tended to favor AEEP without reaching significance (pooled MD 0.65 g/dL; 95% CI -0.33 to 1.63; = 0.103), and transfusion risk was lower but not statistically significant (pooled RR ≈ 0.46; 95% CI 0.18-1.15). PSA reduction was substantial and broadly equivalent between techniques. Functional outcomes (IPSS, QoL, Qmax, PVR) improved comparably with both approaches. Leave-one-out analyses confirmed that the catheterization and length-of-stay advantages of AEEP were robust, and no evidence of publication bias was detected. Certainty of evidence was low to moderate, reflecting the observational designs. Leave-one-out analyses indicated that the catheterization and length-of-stay differences were not driven by any single study; publication bias could not be assessed reliably because fewer than ten studies contributed to any outcome. Certainty of evidence was low to moderate, reflecting the observational designs, the small number of studies, and substantial between-study heterogeneity, and the findings should be regarded as hypothesis-generating. : In large-volume BPH, AEEP and RASP/MISP achieve comparable functional improvement and adenoma debulking, but AEEP offers superior perioperative efficiency, with markedly shorter catheterization and hospital stay and at least comparable safety. RASP/MISP remains a valuable option where robotic infrastructure is available but high-volume enucleation expertise is lacking. These findings, drawn from observational evidence of low-to-moderate certainty, support AEEP as the more resource-efficient minimally invasive option for very large glands and underline the need for randomized comparative trials. - Source: PubMed
Publication date: 2026/07/06
Tsokkou SophiaSieberer ManuelaKonstantinidis IoannisOswald DavidKeramas AntoniosRamesmayer ChristianPeters Julia KatharinaLusuardi LukasToutziaris ChrysovalantisSountoulides Petros - Coronary artery disease (CAD) remains the leading global cause of cardiovascular mortality. Although single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) is widely used, progress in artificial intelligence (AI)-based diagnostic tools is constrained by the limited availability of modern, high-quality, and consistently labeled imaging datasets. - Source: PubMed
Publication date: 2026/06/01
Rahimian AbdurrahimMoslehi MasoudRabbani HosseinEtehadtavakol MahnazDehghani Tohid